A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT04623775 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

468

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Metastatic Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Relatlimab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Paclitaxel
DRUG: Nab-Paclitaxel
DRUG: Pemetrexed

Sponsor

Bristol-Myers Squibb